Roche announces collaboration for phase 3 Alzheimer’s prevention trial

In a company release, Roche announced a collaboration on a new phase 3 Alzheimer’s disease prevention trial, which will test an investigational subcutaneous anti-amyloid antibody.
The pharmaceutical company will partner with Banner Alzheimer’s Institute’s Alzheimer’s Prevention Initiative, Massachusetts General Hospital and the University of Southern California Alzheimer’s Therapeutic Research Institute for SKYLINE, a secondary prevention trial, which seeks to evaluate the potential of gantenerumab to slow disease progression in people presenting with the earliest

In a company release, Roche announced a collaboration on a new phase 3 Alzheimer’s disease prevention trial, which will test an investigational subcutaneous anti-amyloid antibody.
The pharmaceutical company will partner with Banner Alzheimer’s Institute’s Alzheimer’s Prevention Initiative, Massachusetts General Hospital and the University of Southern California Alzheimer’s Therapeutic Research Institute for SKYLINE, a secondary prevention trial, which seeks to evaluate the potential of gantenerumab to slow disease progression in people presenting with the earliest